NasdaqCM - Delayed Quote USD
Immunome, Inc. (IMNM)
9.57
+0.30
+(3.24%)
At close: June 10 at 4:00:01 PM EDT
9.53
-0.04
(-0.42%)
After hours: June 10 at 7:03:53 PM EDT
Insider Purchases Last 6 Months
| Shares | Transactions | |
|---|---|---|
| Purchases | 0 | 0 |
| Sales | -- | 0 |
| Net Shares Purchased (Sold) | 0 | 0 |
| Total Insider Shares Held | 9.99M | -- |
| % Net Shares Purchased (Sold) | -- | -- |
Net Institutional Purchases Prior Quarter to Latest Quarter
| Shares | |
|---|---|
| Net Shares Purchased (Sold) | -- |
| % Change in Institutional Shares Held | -- |
Insider Transactions Reported - Last Two Years
| Insider | Transaction | Type | Value | Date |
|---|---|---|---|---|
| BIENAIME JEAN-JACQUES Director | Purchase at price 9.38 per share. | Direct | 46,900 | Jun 3, 2025 |
| HIGGINS JACK Officer | Conversion of Exercise of derivative security at price 1.35 per share. | Direct | 7,020 | Mar 27, 2025 |
| SIEGALL CLAY B Chief Executive Officer | Purchase at price 7.29 per share. | Direct | 999,459 | Mar 26, 2025 |
| BIENAIME JEAN-JACQUES Director | Purchase at price 7.78 per share. | Direct | 60,684 | Mar 25, 2025 |
| BIENAIME JEAN-JACQUES Director | Purchase at price 8.21 per share. | Direct | 57,470 | Mar 24, 2025 |
| TSAI PHILIP S. L. Chief Technology Officer | Purchase at price 8.42 per share. | Direct | 103,566 | Mar 24, 2025 |
| SIEGALL CLAY B Chief Executive Officer | Purchase at price 11.03 per share. | Direct | 1,654,500 | Jan 31, 2025 |
| SIEGALL CLAY B Chief Executive Officer | Purchase at price 9.54 - 9.78 per share. | Direct | 962,181 | Nov 22, 2024 |
| LECHLEIDER ROBERT M.D. Officer | Purchase at price 9.48 per share. | Direct | 149,800 | Nov 21, 2024 |
| TSAI PHILIP S. L. Chief Technology Officer | Purchase at price 9.43 per share. | Direct | 198,030 | Nov 21, 2024 |
| ROSETT MAX Chief Financial Officer | Conversion of Exercise of derivative security at price 1.05 per share. | Direct | 44,100 | Sep 19, 2024 |
| ROSETT MAX Chief Financial Officer | Sale at price 16.01 per share. | Direct | 230,224 | Sep 19, 2024 |
| HIGGINS JACK Officer | Stock Gift at price 0.00 per share. | Direct | 0 | Aug 19, 2024 |
| BIENAIME JEAN-JACQUES Director | Purchase at price 13.94 per share. | Direct | 97,608 | Aug 16, 2024 |
| HIGGINS JACK Officer | Conversion of Exercise of derivative security at price 1.35 per share. | Direct | 26,357 | Aug 15, 2024 |
| HIGGINS JACK Officer | Sale at price 13.92 per share. | Direct | 49,072 | Aug 15, 2024 |
| BIENAIME JEAN-JACQUES Director | Purchase at price 13.57 per share. | Direct | 27,140 | May 21, 2024 |
| SIEGALL CLAY B Chief Executive Officer | Purchase at price 13.78 - 13.91 per share. | Direct | 1,388,072 | May 21, 2024 |
| SIEGALL CLAY B Chief Executive Officer | Purchase at price 8.20 per share. | Direct | 1,387,473 | Oct 2, 2023 |
| TURNER BRUCE C Officer | Purchase at price 8.20 per share. | Direct | 346,860 | Oct 2, 2023 |
| PRENDERGAST FRANKLYN G Director | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Oct 2, 2023 |
| RAPP MICHAEL Director | Stock Award(Grant) at price 8.20 per share. | Direct | 2,081,209 | Oct 2, 2023 |
Related Tickers
MRSN Mersana Therapeutics, Inc.
0.4070
+4.15%
ZYME Zymeworks Inc.
13.07
+4.98%
TSHA Taysha Gene Therapies, Inc.
2.6100
-6.79%
CGEM Cullinan Therapeutics, Inc.
9.03
+3.08%
NGNE Neurogene Inc.
21.58
+8.39%
BCAX Bicara Therapeutics Inc.
12.58
+9.58%
COGT Cogent Biosciences, Inc.
7.42
+7.54%
ATXS Astria Therapeutics, Inc.
5.71
-1.38%
ALMS Alumis Inc.
3.3600
-2.04%
OCUL Ocular Therapeutix, Inc.
8.91
+0.11%